What Is Semax? Uses, Benefits, Safety, FDA Status, and Evidence
Medical review note: This article is for educational purposes only and does not provide medical advice. Semax is not FDA-approved for human therapeutic use in the United States. Products sold online as Semax, Semax acetate, ACTH(4-10) analog, nasal Semax, or “research use only” Semax may carry safety, quality, legal, and regulatory risks.
Quick answer
Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone, also called ACTH. It is usually described as an ACTH(4-10) analog with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, sometimes written as MEHFPGP. Semax has been studied mainly in Russian clinical and preclinical research for ischemic stroke, neuroprotection, cognition, memory, optic nerve disease, stress response, BDNF-related signaling, and gene-expression effects. Some studies suggest neuroprotective and nootropic-like activity, but the evidence base is limited, geographically concentrated, and not enough to make Semax a standard FDA-approved neurological or cognitive treatment. Semax is not FDA-approved in the U.S., and FDA says compounded drugs containing Semax may pose immunogenicity risk because of potential aggregation and peptide-related impurities, while FDA has no or limited safety-related information for proposed routes of administration.
Key facts about Semax
| Question | Answer |
|---|---|
| What is Semax? | A synthetic ACTH(4-10)-derived heptapeptide studied for neuroprotection, cognition, stroke, and gene-expression effects. |
| Other names | Semax acetate, ACTH(4-10) analog, ACTH(4-7)-PGP, MEHFPGP, Met-Glu-His-Phe-Pro-Gly-Pro. |
| Peptide class | Synthetic neuropeptide / ACTH fragment analog / nootropic research peptide / neuroprotective research peptide. |
| Main mechanism | Proposed effects on BDNF/TrkB signaling, melanocortin-related pathways, gene expression, neuroinflammation, ischemia response, and neurotransmitter systems. |
| FDA-approved? | No. Semax is not an FDA-approved drug in the United States. |
| Main studied uses | Ischemic stroke, transient ischemic attack, cognition, memory, optic nerve disease, neuroprotection, stress response, and gene-expression modulation. |
| Human evidence level | Limited human evidence, mostly Russian clinical literature; not enough for FDA-approved stroke, cognition, ADHD, or nootropic claims. |
| Animal/lab evidence level | Moderate preclinical evidence for neuroprotective, ischemia-related, BDNF-related, and gene-expression effects. |
| Common online claims | “Nootropic peptide,” “focus peptide,” “memory peptide,” “BDNF peptide,” “stroke recovery peptide,” “neuroprotective peptide,” “dopamine support.” |
| Sports status | Not found here as specifically named on the WADA prohibited list; athletes should verify current WADA/Global DRO status before use. |
| Main safety concern | Limited U.S.-standard clinical safety evidence, FDA-identified immunogenicity and impurity concerns for compounded Semax, limited safety information for proposed routes, and risks from unapproved online products. |
What is Semax?
Semax is a synthetic heptapeptide derived from ACTH(4-10). ACTH is adrenocorticotropic hormone, a pituitary hormone involved in adrenal signaling. Semax is not the full ACTH hormone. It is a short synthetic analog of an ACTH fragment.
Semax is commonly described by the sequence:
Met-Glu-His-Phe-Pro-Gly-Pro
It is also written as MEHFPGP or ACTH(4-7)-PGP in some scientific literature.
A PubMed-indexed study on Semax and ACTH(4-10) describes Semax as an ACTH(4-10) analog with cognitive effects and discusses BDNF/TrkB-related signaling. A PMC gene-expression study studied how Semax affects expression of genes related to immune and vascular-system function.
The key distinction:
Semax is a neuropeptide research compound with interesting biology, but it is not an FDA-approved nootropic, ADHD drug, stroke medication, or brain-repair treatment in the United States.
How does Semax work?
Semax’s mechanism is not fully established. The literature discusses several possible pathways:
- BDNF and TrkB signaling
- Melanocortin-related pathways
- Gene-expression effects
- Neuroinflammation modulation
- Ischemia-response pathways
- Dopaminergic signaling
- Serotonergic signaling
- Neurotrophic and neuroprotective effects
- Enkephalinase-related effects
- Immune and vascular-system gene regulation
A PubMed-indexed study suggested that Semax may affect cognitive brain functions by modulating hippocampal BDNF/TrkB signaling. A PMC study found that Semax affected gene expression related to immune and vascular systems.
In plain English:
Semax is studied because it may influence neurotrophic, inflammatory, vascular, and neurotransmitter-related pathways involved in brain stress and recovery.
But mechanism is not proof.
A proposed BDNF, dopamine, or neuroprotection mechanism does not prove that Semax safely improves focus, treats ADHD, repairs the brain, prevents stroke, reverses cognitive decline, improves memory, or works as a reliable nootropic in healthy people.
What is Semax used for?
Semax is commonly discussed for stroke, neuroprotection, cognition, focus, ADHD-like symptoms, memory, optic nerve disease, and nootropic use. These uses differ sharply in evidence quality.
| Use | Evidence level | What is known | What is not known | |---|---|---| | Ischemic stroke | Limited regional human evidence / stronger preclinical interest | Russian literature and reviews discuss Semax use in ischemic stroke and recovery. | It is not FDA-approved for stroke, and strong independent international clinical evidence is limited. | | Neuroprotection | Preclinical / mechanistic | Animal and cell studies suggest neuroprotective effects in ischemia and injury models. | Human neuroprotection benefit is not established by FDA-standard trials. | | Cognition and memory | Preclinical plus limited human context | Studies discuss BDNF, gene expression, and cognitive effects. | It is not proven as a cognitive enhancer in healthy people. | | ADHD / focus | Weak / marketing-driven | Online claims are common. | Strong clinical evidence for ADHD treatment is lacking. | | Optic nerve disease | Limited regional clinical context | Some Russian literature discusses optic nerve-related use. | Not FDA-approved for ophthalmic disease. | | Depression or mood | Preclinical / weak | Animal studies and mechanistic work suggest monoamine-related effects. | Human depression-treatment evidence is inadequate. | | Anti-aging | Unsupported | Some nootropic claims extrapolate from neurotrophic biology. | No strong evidence supports Semax as an anti-aging therapy. | | Online research-use Semax | High uncertainty | Sellers market it as nasal spray, drops, or research peptide. | Quality, sterility, identity, dosing, and safety may be unknown. |
What does the research show?
Human evidence for stroke and neurological use
Semax has some human clinical literature, but the evidence base is limited and heavily concentrated in Russian research.
A PMC review on ACTH(4-7)PGP, also known as Semax states that a clinical study showed efficacy of Semax in patients with ischemic stroke and that the peptide improved functional recovery and motor performance. However, review-level discussion is not the same as broad independent clinical validation across modern international stroke trials.
The Alzheimer’s Drug Discovery Foundation Semax report notes that Semax has been shown to improve clinical outcomes following stroke in studies from Russia, but also states that published literature of well-conducted studies is lacking and that little human evidence exists for potential side effects.
The practical interpretation:
Semax has real stroke-focused research, but it is not supported by the kind of large, multi-center, FDA-standard evidence base used for approved stroke or neurological therapies.
Evidence for cognition and BDNF signaling
Semax is often marketed as a nootropic because of research on memory, cognition, and neurotrophic signaling.
A PubMed-indexed paper reported that Semax affected BDNF and TrkB-related signaling in the hippocampus. A 2025 PMC study evaluated Semax and a derivative in mouse models and reported cognitive-function effects in behavioral tests.
The practical interpretation:
Semax has plausible nootropic mechanisms, but animal cognition studies and BDNF signaling do not prove reliable cognitive enhancement in humans.
Gene-expression and ischemia research
Semax has been studied for its effects on gene expression in ischemia and related models.
A PubMed-indexed study states that Semax is an ACTH(4-7)-derived peptide and discusses gene-expression regulation in a cerebral ischemia model. A PMC study found that ACTH-like peptides affected rat brain gene-expression profiles disrupted by experimental ischemia.
The practical interpretation:
Gene-expression findings are scientifically interesting, but they do not establish Semax as an approved treatment for stroke, brain injury, migraine, ADHD, or cognitive decline.
Animal and mechanistic evidence
Preclinical evidence supports Semax’s biological activity in neuroprotection and stress-related models.
A PubMed-indexed study described Semax as a synthetic ACTH(4-10) analog with marked nootropic and neuroprotective activities in preclinical research.
The practical interpretation:
Animal and mechanistic studies support biological plausibility, but they do not prove clinical safety or efficacy for consumer Semax products.
FDA safety and compounding context
FDA has specifically flagged Semax in the compounding-risk context.
The FDA page on bulk drug substances that may present significant safety risks states that compounded drugs containing Semax may pose immunogenicity risk for certain routes of administration because of potential aggregation and peptide-related impurities. FDA also states that it has no or limited safety-related information for proposed routes of administration and lacks sufficient information to know whether Semax would cause harm if administered to humans.
The practical interpretation:
Semax should not be treated as a harmless nasal nootropic. FDA has identified safety-data gaps and product-characterization concerns for compounded Semax.
Evidence summary
| Claim | Evidence verdict | Explanation |
|---|---|---|
| “Semax is an ACTH fragment analog.” | Supported | Semax is commonly described as an ACTH(4-10) or ACTH(4-7)-PGP analog. |
| “Semax has neuroprotective effects.” | Supported preclinically; limited human context | Animal and regional clinical literature support interest, but broad FDA-standard evidence is lacking. |
| “Semax treats ischemic stroke.” | Not established as a U.S. approved claim | It has been studied in stroke, but it is not FDA-approved for stroke in the U.S. |
| “Semax increases BDNF.” | Supported preclinically | Research discusses BDNF/TrkB-related effects, but clinical relevance varies. |
| “Semax is a nootropic.” | Weak to limited | Some cognitive/nootropic-like findings exist, but broad cognitive-enhancement claims are not proven. |
| “Semax treats ADHD.” | Unsupported | ADHD claims are mostly online marketing and extrapolation. |
| “Semax is FDA-approved.” | False | Semax is not FDA-approved in the U.S. |
| “Semax is safe because it is a peptide.” | False | FDA has identified immunogenicity, impurity, and safety-information concerns for compounded Semax. |
| “Semax is banned in sports.” | Not specifically found here | It was not found here as specifically named on WADA’s prohibited list, but athletes should verify. |
| “Research-use Semax is clinically proven.” | False | Research-use products are not FDA-approved consumer therapeutic products. |
Is Semax FDA-approved?
No. Semax is not FDA-approved in the United States.
There is no FDA-approved Semax product for stroke, transient ischemic attack, brain injury, migraine, ADHD, cognition, memory, depression, anxiety, optic nerve disease, or nootropic use.
The FDA compounding safety-risk page states that compounded drugs containing Semax may pose immunogenicity risk for certain routes of administration because of potential aggregation and peptide-related impurities. FDA also says it has no or limited safety-related information for proposed routes of administration.
The key distinction:
Semax is an experimental or regionally used neuropeptide, not an FDA-approved prescription medication in the United States.
Is Semax legal?
Semax’s legal status depends on product type, intended use, jurisdiction, and how it is sold.
The practical answer is simple:
Semax is not an FDA-approved drug in the U.S., and online availability does not mean it is legally marketed for human therapeutic use.
Some sellers market Semax as a research peptide, nootropic spray, or peptide therapy product. That does not make it safe, approved, legal, or appropriate for consumer use.
The blunt version:
Buying “research use only” Semax online is not the same as receiving an FDA-approved neurological or psychiatric medication from a legitimate pharmacy.
Is Semax banned in sports?
I did not find Semax specifically named on the WADA prohibited list in the sources reviewed here.
However, athletes should be careful for three reasons:
- Peptide products can be contaminated or mislabeled.
- Anti-doping status can change.
- Non-approved pharmacologic substances can create risk depending on classification, route, and intended use.
The WADA Prohibited List should be checked directly before use.
The practical advice:
Athletes should verify Semax through Global DRO, WADA, or USADA before using it and should avoid unapproved online peptide products.
Safety and side effects
Semax should not be treated as risk-free.
Possible or theoretical concerns include:
- Nasal irritation for intranasal products
- Headache
- Dizziness
- Fatigue
- Nausea
- Mood changes
- Agitation or overstimulation
- Sleep disturbance
- Blood-pressure or vascular effects uncertainty
- Neurotransmitter-related effects
- Drug-interaction uncertainty
- Unknown long-term neurological safety
- Immunogenicity risk
- Peptide aggregation risk
- Peptide-related impurities
- Product-quality and sterility risks from online sources
- Mislabeling or incorrect concentration
The biggest safety issue is uncertainty.
FDA says it has no or limited safety-related information for proposed routes of Semax administration and lacks sufficient information to know whether the drug would cause harm if administered to humans.
A serious evaluation of Semax should separate controlled research from online peptide/nootropic marketing.
Semax vs similar peptides and drugs
| Compound | Category | Main difference |
|---|---|---|
| Semax | ACTH-derived synthetic heptapeptide | Studied for neuroprotection, stroke, cognition, BDNF signaling, and gene-expression effects. |
| Selank | Tuftsin-related synthetic heptapeptide | Studied more for anxiety, stress response, and immune modulation. |
| N-Acetyl Semax Amidate | Modified Semax derivative | Marketed as a more stable or potent derivative, but human clinical evidence is limited. |
| Cortexin | Peptide-containing neuroprotective drug in some regions | Different compound category and evidence base. |
| Cerebrolysin | Peptide mixture | Studied for stroke and neurodegenerative conditions; not the same as Semax. |
| Modafinil | Wakefulness-promoting drug | FDA-approved for specific sleep disorders, not a peptide. |
| ADHD stimulants | Prescription psychostimulants | FDA-approved examples exist; different mechanism and evidence base. |
| SSRIs/SNRIs | Standard psychiatric drugs | Larger evidence base for many psychiatric conditions; not nootropic peptides. |
The key distinction:
Semax belongs in the neuropeptide/neuroprotective research category. It is not a GLP-1 drug, growth hormone peptide, cosmetic peptide, or FDA-approved cognitive enhancer.
Why is Semax sold as “research use only”?
Some online sellers use “research use only” language to sell Semax outside normal prescription-drug channels.
That label is not a trust signal.
A serious reader should understand this distinction:
| Product type | What it means |
|---|---|
| Laboratory Semax | Research peptide used in controlled experimental settings. |
| Regionally used Semax | Semax has been used or studied in some non-U.S. contexts, especially Russia. |
| FDA-approved Semax | Does not currently exist in the U.S. |
| Compounded Semax | FDA has raised immunogenicity, impurity, and safety-information concerns. |
| Research-use Semax | Not an FDA-approved consumer therapeutic product. |
| Online nasal Semax | Higher risk for identity, purity, sterility, concentration, and dosing problems. |
How to evaluate Semax claims online
| Claim | What to verify |
|---|---|
| “FDA-approved Semax” | False in the U.S. Semax is not FDA-approved. |
| “Clinically proven nootropic” | Check whether evidence is from large modern clinical trials or small/regional studies. |
| “Repairs the brain” | Too broad. Neuroprotection mechanisms do not prove brain repair in humans. |
| “Treats stroke” | Not an FDA-approved claim in the U.S.; look for strong independent clinical trials. |
| “Boosts BDNF” | Check whether the evidence is animal, cell, biomarker, or human clinical outcome data. |
| “Treats ADHD” | Unsupported unless backed by controlled ADHD trials. |
| “No side effects” | Unsupported. FDA has safety-data concerns, and long-term human safety is not established. |
| “Research use only” | This does not mean safe, legal, approved, or appropriate for human use. |
| “Safe for athletes” | Verify through WADA, USADA, or Global DRO before use. |
| “Third-party tested” | Ask for batch-specific HPLC, LC-MS, identity, purity, sterility, endotoxin, microbial, and stability data. |
Bottom line
Semax is a synthetic ACTH-derived heptapeptide studied for neuroprotection, ischemic stroke, cognition, BDNF/TrkB signaling, gene expression, and stress-response biology. Some regional clinical and preclinical studies suggest neurological effects, but the evidence base is not equivalent to large, independent FDA-standard clinical programs.
The most defensible conclusion is:
Semax is a legitimate neuropeptide research compound with interesting neuroprotective and nootropic-like biology, but it is not an FDA-approved stroke treatment, ADHD medication, cognitive enhancer, or brain-repair therapy in the U.S. FDA has flagged compounded Semax for immunogenicity, impurity, and safety-information concerns, so online Semax products should be treated as high-risk rather than as harmless “focus and BDNF” sprays.
FAQ
What is Semax?
Semax is a synthetic ACTH(4-10)-derived heptapeptide. It is studied for neuroprotection, ischemic stroke, cognition, BDNF-related signaling, gene expression, and stress-response biology.
What does Semax do?
Semax is proposed to affect BDNF/TrkB signaling, gene expression, neuroinflammation, ischemia-response pathways, and neurotransmitter systems. Human clinical significance remains uncertain.
Is Semax FDA-approved?
No. Semax is not FDA-approved in the United States. FDA says compounded drugs containing Semax may pose immunogenicity risk and that FDA has no or limited safety-related information for proposed routes of administration.
Is Semax used for stroke?
Semax has been studied and regionally used in stroke-related contexts, especially in Russian literature. It is not FDA-approved for stroke in the U.S.
Is Semax a nootropic?
Semax is often marketed as a nootropic peptide, and some research discusses cognitive and neurotrophic effects. However, strong human evidence for cognitive enhancement in healthy people is lacking.
Does Semax increase BDNF?
Preclinical research suggests Semax may influence BDNF/TrkB signaling. This does not prove reliable cognitive or neurological benefit in humans.
Is Semax the same as Selank?
No. Semax and Selank are both synthetic neuropeptides studied in Russian research contexts, but they are different compounds. Semax is ACTH-derived, while Selank is related to tuftsin.
Is Semax safe?
Semax does not have enough U.S.-standard long-term human safety data to call it safe for consumer use. FDA has raised concerns about immunogenicity, peptide aggregation, peptide-related impurities, and limited safety information.
Is Semax legal?
Semax is not an FDA-approved drug in the U.S. Online sales as a research peptide do not mean it is legally marketed for human therapeutic use.
Is Semax banned in sports?
I did not find Semax specifically named on the WADA prohibited list in the sources reviewed here. Athletes should verify current status with WADA, USADA, or Global DRO before use.
Why do sellers call Semax “research use only”?
Sellers often use “research use only” language because Semax is not FDA-approved for consumer therapeutic use in the U.S. The phrase does not make the product safe, legal, approved, or clinically proven.
What is the biggest risk with Semax?
The biggest risks are using an unapproved neuroactive peptide without adequate safety data, relying on limited regional or animal studies instead of FDA-standard evidence, and buying online products with uncertain identity, purity, sterility, concentration, and stability.
Sources
- FDA: Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
- FDA: July 23-24, 2026 Pharmacy Compounding Advisory Committee Meeting
- PubMed: Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF/TrkB signaling
- PMC: The peptide Semax affects expression of genes related to immune and vascular systems
- PubMed: Semax, synthetic ACTH(4-10) analogue, attenuates experimental cerebral ischemia effects
- PubMed: Semax, an analog of ACTH(4-7), regulates expression of immune and vascular genes during cerebral ischemia
- PMC: Novel Insights into the Protective Properties of ACTH(4-7)PGP, Semax
- PMC: ACTH-like peptides compensate rat brain gene expression profile disrupted by ischemia
- PMC: The Potential of the Peptide Drug Semax and Its Derivative for Cognitive Function
- PubMed: The peptide drug ACTH(4-7)PGP, Semax, suppresses inflammatory gene expression
- Alzheimer’s Drug Discovery Foundation: Semax Cognitive Vitality Report
- WADA: Prohibited List
- WADA: 2026 Prohibited List
Frequently asked questions
What is Semax?
Semax is a synthetic ACTH(4-10)-derived heptapeptide. It is studied for neuroprotection, ischemic stroke, cognition, BDNF-related signaling, gene expression, and stress-response biology.
Is Semax FDA-approved?
No. Semax is not FDA-approved in the United States. FDA says compounded drugs containing Semax may pose immunogenicity risk and that FDA has no or limited safety-related information for proposed routes of administration.
Is Semax used for stroke?
Semax has been studied and regionally used in stroke-related contexts, especially in Russian literature. It is not FDA-approved for stroke in the U.S.
Is Semax a nootropic?
Semax is often marketed as a nootropic peptide, and some research discusses cognitive and neurotrophic effects. However, strong human evidence for cognitive enhancement in healthy people is lacking.
Does Semax increase BDNF?
Preclinical research suggests Semax may influence BDNF/TrkB signaling. This does not prove reliable cognitive or neurological benefit in humans.
Is Semax the same as Selank?
No. Semax and Selank are both synthetic neuropeptides studied in Russian research contexts, but they are different compounds. Semax is ACTH-derived, while Selank is related to tuftsin.
Is Semax safe?
Semax does not have enough U.S.-standard long-term human safety data to call it safe for consumer use. FDA has raised concerns about immunogenicity, peptide aggregation, peptide-related impurities, and limited safety information.
Is Semax banned in sports?
No official WADA source was found here specifically naming Semax as prohibited. Athletes should verify current status with WADA, USADA, or Global DRO before use.
Sources
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]WADA: Prohibited List
Anti Doping
- [13]WADA: 2026 Prohibited List
Anti Doping
Last updated May 9, 2026